Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

Lancet
Laura M SpringAditya Bardia

Abstract

The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer represents a major milestone in cancer therapeutics. Three different oral CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, have significantly improved progression-free survival by a number of months when combined with endocrine therapy. More recently, improvement in overall survival has been reported with ribociclib and abemaciclib. The toxicity profile of all three drugs is well described and generally easily manageable with dose reductions when indicated. More myelotoxicity is observed with palbociclib and ribociclib, but more gastrointestinal toxicity is observed with abemaciclib. Emerging data is shedding light on the resistance mechanisms associated with CDK4/6 inhibitors, including cell cycle alterations and activation of upstream tyrosine kinase receptors. A number of clinical trials are exploring several important questions regarding treatment sequencing, combinatorial strategies, and the use of CDK4/6 inhibitors in the adjuvant and neoadjuvant settings, thereby further expanding and refining the clinical applicati...Continue Reading

Citations

Jul 23, 2020·Breast Cancer Research and Treatment·Arkadiusz Z DudekRuth M O'Regan
May 18, 2020·Angewandte Chemie·Mingxing TengNathanael S Gray
Oct 6, 2020·Frontiers in Pharmacology·Shengnan BaoYongmei Yin
Aug 30, 2020·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Ryohei OgataJunichi Kurebayashi
Sep 5, 2020·International Journal of Molecular Sciences·Rossana RoncatoGiuseppe Toffoli
Sep 10, 2020·International Journal of Molecular Sciences·Michela PiezzoMichelino De Laurentiis
May 10, 2020·British Journal of Cancer·Amelia McCartney, Luca Malorni
Oct 6, 2020·Frontiers in Oncology·Shuang DongSheng Hu
Sep 12, 2020·Breast Cancer Research and Treatment·Pietro SollenaUNKNOWN European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group
Aug 23, 2020·Current Opinion in Oncology·Dario Trapani, Giuseppe Curigliano
Oct 22, 2020·Expert Review of Anticancer Therapy·Patrick NevenGuy Jerusalem
Aug 5, 2020·Journal of the National Cancer Institute·Maria Alice FranzoiEvandro de Azambuja
Jan 15, 2021·Nature Medicine·Karuna Ganesh, Joan Massagué
Dec 19, 2020·Cancer Cell·Giulia PetroniLorenzo Galluzzi
Jan 24, 2021·Cancer Cell International·Yi GaoJing Zhang
Jan 8, 2021·Molecular Biology Reports·Georgia GomatouElias Kotteas
Feb 12, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Agostinetto, M Ignatiadis
Feb 9, 2021·World Journal of Clinical Oncology·Guillermo Arturo ValenciaRodrigo Auqui
Dec 29, 2020·The New England Journal of Medicine·Harold J Burstein
Mar 5, 2021·European Journal of Clinical Investigation·Elisa AgostinettoEvandro de Azambuja
Mar 26, 2021·Current Oncology Reports·Elisa AgostinettoEvandro de Azambuja
Mar 30, 2021·Frontiers in Oncology·Suryendu SahaSomsubhra Nath
Nov 4, 2020·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jieun LeeJae Ho Byun
May 8, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Martina SilvestriNorma Cameli
Sep 19, 2020·Molecular Cell·Seth M RubinJan M Skotheim
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicolò Matteo Luca BattistiAlistair Ring
Jun 1, 2021·Signal Transduction and Targeted Therapy·Lei ZhongShengyong Yang
Jun 3, 2021·Journal of Personalized Medicine·Miriam González-CondeClotilde Costa
May 18, 2021·Journal of Pharmaceutical and Biomedical Analysis·C Louwrens BraalStijn L W Koolen
Jun 3, 2021·Cells·Mattia GaruttiFabio Puglisi
Jun 10, 2021·Therapeutic Advances in Musculoskeletal Disease·Hangzhan MaZhenfeng Duan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.